

Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.: L74899DL1993PLC056594

**Ref: STEX/RPT/2022-23**

**Dated 23.11.2022**

**BSE Limited  
Floor 25, P J Towers  
Dalal Street  
Mumbai-400001**

**National Stock Exchange of India Ltd  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051**

**BSE Code-531146**

**NSE Code: MEDICAMEQ**

**Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith details of related party transactions on consolidated basis for the half year ended on September 30, 2022.

You are requested to take the same on record.

Thanking You

Yours truly,  
**For Medicamen Biotech Limited**

**Parul Choudhary  
Company Secretary  
ACS44157**

[Home](#)[Validate](#)

General information about company			
Name of The Company	MEDICAMEN BIOTECH LIMITED		
BSE Scrip Code	531146		
NSE Symbol	MEDICAMEQ		
MSE Symbol	NA		
Date of Start of Financial Year	01	04	2022
Date of End of Financial Year	31	03	2023
Reporting Period	First half yearly		
Date of Start of Reporting Period	01	04	2022
Date of End of Reporting Period	30	09	2022
Level of rounding to be used in disclosing related party transactions	Lakhs		
Whether the company has any related party?	Yes		
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes		

<b>(I)</b> We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
<b>(II)</b> We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
<b>(III)</b> Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
<b>(a)</b> If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
<b>(b)</b> If answer to above question is No, please explain the reason for not complying.	

